


March 26, 2015

CIRM

CALIFORNIA'S STEM CELL AGENCY



C. Randal Mills, Ph.D.

President and Chief Executive Officer
California Institute for Regenerative Medicine

Topics



DISCOVERY
TRANSLATIONAL
CLINICAL
EDUCATION
INFRASTRUCTURE

- Mission
- CIRM 2.0 Clinical Update
- CIRM 2.0 Discovery and Translational Update
- Loan and Grant Program Modification Update
- Things to Come

Our Mission

Accelerating stem cell treatments to patients with unmet medical needs.

CIRM 2.0 Mission Validation Testing

When taking action, we consider what impact our efforts will have in these areas:



CIRM 2.0 Mission Validation Testing

When taking action, we consider what impact our efforts will have in these areas:


Will it speed up the development of a stem cell treatment?



CIRM 2.0 Mission Validation Testing

When taking action, we consider what impact our efforts will have in these areas:


Will it increase the likelihood of success?



CIRM 2.0 Mission Validation Testing

When taking action, we consider what impact our efforts will have in these areas:


Will it fill an unmet medical needs?



CIRM 2.0 Mission Validation Testing

When taking action, we consider what impact our efforts will have in these areas:

Is it efficient?






2.0 CLINICAL UPDATE

CIRM 2.0 – Starting with Clinical



Clinical Stage has Three Programs

CLINICAL STAGE



PA15-01



PA15-02



PA15-03

Review Cycle Progress

Clinical Program

Month	Submission Day 0	Screening Day 7	Budget Review Day 21	Sent to GWG Day 30	GWG Score Day 60	CIRM Rec Day 70	ICOC Decision Day 81	Contract Signed Day 120
January	2 15-02	1 Passed 1 Failed	1 Passed	1 Sent	March 30th	April 10th	April 23rd	Pending
February	1 15-01 1 15-02	15-01 P 15-02 F	1 Passed	April 1 st	April 27 th	May 8th	May 21st	Pending
Within Target	NA	4/4	2/2	1/1	Pending	Pending	Pending	Pending

CIRM 2.0 Clinical “Punch List”

- Clarify the types of therapies that are eligible
- Co-funding documentation
- Matching is on total project costs
- Request more detailed enrollment projections
- Add an immediate grant counseling step



2.0 DISCOVERY AND TRANSLATIONAL UPDATE

CIRM 2.0 Discovery and Translational Target Attributes

- Predictable Requests for Applications
- Responsive to New Developments or Downstream Needs
- Multiple Outflow Pathways from Discovery
- Linking Grants Seamlessly
- Motivating Quick Baton Passing
- Includes Significant Opportunities for Training
- Meaningful Incentive for Achieving CIRM Objectives



LOAN AND GRANT PROGRAM MODIFICATION UPDATE

Loan and Grant Modifications Being Explored

Primary objective is to provide fair funding mechanisms that do not inadvertently dissuade partnering with CIRM

- Exploring the combination of the loan and grant programs into a single, streamlined process
 - Allows the recipient to elect to convert a grant into a loan
 - Addresses royalty vs. balance sheet concerns
 - Substantially streamlines the loan process
 - Loan process currently still in discussion



THINGS TO COME

Coming Soon

April


- First Consideration of Award under CIRM 2.0
- First In-Person Clinical Program GWG Review

May

- 2016 Budget Review (Finance Subcommittee)
- Strategic Planning Discussion
- 2016 Budget Adoption

July

- CIRM 2.0 Discovery and Translational Stage Program Concept Plans
- Creativity and Bridges Concept Plans
- Finalize Strategic Plan



For more information contact
Dr. Gil Sambrano at
GSambrano@cirm.ca.gov